Medical Education Division
Our Products
On-Line Store

Google
 
Web www.brooksidepress.org

Operational Medicine 2001
Ranitadine (Zantac)

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Phone Consultation  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

 
 

Category:

  • Gastrointestinal

Description:

  • Antiulcer agent (H2 antagonist)

Indications:

  • Duodenal ulcer; benign gastric ulcer

  • Pathological hypersecretory conditions (Zollinger-Ellison syndrome)

  • Gastroesophageal reflux disease (GERD)

  • Erosive gastritis

  • Stress ulcer prophylaxis

Drug Interactions:

  • Reduced efficacy: cefuroxine, cefpodoxime

  • Enhanced hypoglycemic effect: glipizide

  • Increased bioavailability: nifedipine, nitrendipine, nisoldipine

  • Decreased plasma concentrations: ketoconazole, enoxacin

Precautions:

  • Pregnancy category B; compatible with breast feeding

  • Stagger doses of ranitadine and antacids

Adverse Reactions (Side Effects):

  • CNS: dizziness, insomnia, malaise, somnolence, vertigo

  • CV: atrioventricular block, bradycardia, premature ventricular beats, tachycardia

  • GI: Abdominal discomfort or pain, constipation, hepatitis, increased liver function tests, nausea, vomiting, pancreatitis (rare)

  • HEME: granulocytopenia, leukopenia, thrombocytopenia

  • SKIN: alopecia, erythema multiforme (rare), rash

  • MS: arthralgias, myalgias

Dosage:

Administered PO (tablets, gelatin capsules, syrup), IV, and IM

  • Adult: 

    • Duodenal and gastric ulcer: PO 150mg twice daily or 300mg at bedtime for 4-8 weeks, maintenance 150mg every night at bedtime

    • GERD: 

      • PO 150mg twice daily

    • Erosive esophagitis: 

      • PO 150mg four times daily, maintenance 150mg twice daily

    • Pathological hypersecretory conditions: 

      • PO 150mg twice daily initially, titrate to desired response up to 6 grams daily

      • IV INF start 1mg/kg/hr, increase by 0.5mg/kg/hr intervals every 4 hours as needed up to 2.5mg/kg/hr

      • IM/IV 50mg every 6 to 8 hours, do not exceed 400mg per day; 

      • IV INF 6.25mg/hr

  • Child:

    • PO 1.25mg/kg every 12 hours, max 300mg/kg/day

    • IM/IV 0.75-1.5mg/kg every 6-8 hours, max 6mg/kg/day or 300mg/day

    • IV INF 0.1-0.25mg/kg/hr


Approved for public release; Distribution is unlimited.

The listing of any non-Federal product in this CD is not an endorsement of the product itself, but simply an acknowledgement of the source. 

Operational Medicine 2001

Health Care in Military Settings

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates Medical Education Division.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

Contact Us  ·  ·  Other Brookside Products